Physician profile
Alan Zalkowitz
NPI 1760487938
$3,076.18
in general payments reported to CMS, 2019-2025
36 companies · $597 in 2025
The $597 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $360 · 2021: $221 · 2022: $60.46 · 2023: $520 · 2024: $576 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,692.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $410.82 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Abbvie INC. | $378.14 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $325.68 | 2021-2025 | |
| Ucb, INC. | $270.97 | 2020-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $214.66 | 2019-2023 | |
| Janssen Biotech, INC. | $204.16 | 2019-2025 | Tremfya |
| Astrazeneca Pharmaceuticals Lp | $136.76 | 2023-2025 | |
| Depuy Synthes Sales INC. | $119.25 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $105.28 | 2020-2025 | Orencia |
| Vertiflex, INC. | $94.88 | 2019 | |
| Genzyme Corporation | $91.55 | 2019-2025 | |
| Horizon Therapeutics Plc | $85.03 | 2019-2020 | |
| Genentech USA, INC. | $69.99 | 2020 | |
| Alvogen INC | $55.60 | 2023-2025 | Teriparatide |
| Ultragenyx Pharmaceutical INC. | $52.32 | 2022-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $49.39 | 2020 | |
| Glaxosmithkline, LLC. | $44.89 | 2023-2025 | Benlysta, Nucala |
| Boston Scientific Corporation | $37.50 | 2019 | |
| Bioventus LLC | $31.47 | 2024 | Exogen Ultrasound Bone Healing System |
| Zimvie INC. | $31.25 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.23 | 2023-2024 | Cyltezo |
| Integra Lifesciences Corporation | $22.05 | 2020 | |
| Seapearl East, INC | $21.06 | 2025 | |
| Ibsa Pharma INC. | $17.44 | 2025 | Licart, Tirosint, Flector |
| Ani Pharmaceuticals, INC. | $17.19 | 2024 | Purified Cortrophin Gel |
| Radius Health, INC. | $17.00 | 2025 | Tymlos |
| Kyowa Kirin, INC. | $16.99 | 2023 | Crysvita |
| Zimmer Biomet Holdings, INC. | $16.76 | 2020 | |
| Invivyd INC | $15.88 | 2025 | Pemgarda |
| Fidia Pharma USA INC. | $15.79 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $15.06 | 2023 | Exparel, Zilretta, Iovera |
| Hikma Pharmaceuticals USA | $14.99 | 2020 | |
| Endo Pharmaceuticals INC. | $14.31 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.15 | 2022 | |
| Pacira Therapeutics, INC. | $12.29 | 2019 | |
| Royal Biologics, INC. | $10.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Zalkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.